Johnson & Johnson Proposes $5.5 Billion Settlement to Resolve Talcum Powder Cancer Lawsuits

Johnson & Johnson has put forward a proposal to pay as much as $5.5 billion (£4.14 billion) to resolve tens of thousands of legal claims asserting that its talcum-based baby powder and similar products are linked to ovarian cancer.

The proposed agreement, described as a landmark settlement, seeks to bring an end to a protracted legal dispute that has hung over the American healthcare conglomerate for more than a decade. If finalized, it would cover approximately 69,000 cases, representing the majority of remaining talc-related lawsuits against the company.

A Long-Running Legal Battle

Legal action against Johnson & Johnson over its talc-based baby powder traces back to 2009. Consumers and their families have filed lawsuits claiming that the company's talc products caused cancer, pointing to alleged contamination with asbestos—a known carcinogen.

Talc is a naturally occurring mineral composed of magnesium, silicon, oxygen, and hydrogen. It is prized for its soft, soapy texture and has long been a key ingredient in baby powder. However, because talc is mined from the earth, it can be found in geological seams located near asbestos deposits, raising concerns about potential cross-contamination.

The plaintiffs allege that Johnson & Johnson's talc products were contaminated with asbestos, leading to ovarian cancer in users. The company has consistently rejected these accusations.

Terms of the Proposed Settlement

Under the terms outlined by Johnson & Johnson, the firm would offer up to $3 billion next year, with no further payments required before 2028. The total proposed payout could reach $5.5 billion.

However, the settlement is not yet final. Johnson & Johnson stated that the proposal must be accepted by law firms representing at least 95 percent of the ovarian cancer claims currently pending in state and federal courts before it can be formally concluded.

The company indicated that the agreement would encompass roughly 69,000 cases, accounting for most of the remaining talc-related legal claims it faces.

Johnson & Johnson Maintains Its Position

Erik Haas, the company's vice president of litigation, said on Monday that the allegations are "meritless." He expressed confidence that Johnson & Johnson would have "ultimately prevailed with further litigation," noting that the company has won the majority of cases that have been heard in court to date.

Despite this confidence, Haas said the company chose to settle in order to bring the matter to a close. He stated that the proposed resolution "allows the company to put this matter behind it" and enables Johnson & Johnson to "remain focused on its mission to develop medicines and devices that save lives."

Johnson & Johnson has repeatedly denied that its talc-based products cause cancer. In its latest announcement, the company stated: "Studies show talc is safe, does not contain asbestos and does not cause cancer."

The firm also pointed to a recent legal victory. Earlier in July, a federal court ruled in Johnson & Johnson's favor by questioning whether individual plaintiffs could demonstrate that talc was the direct cause of their ovarian cancer.

From Talc to Cornstarch

Johnson & Johnson has already taken steps to move away from talc-based products. In 2022, the company announced it would cease manufacturing and selling its talc-based baby powder globally. That decision came more than two years after the company had already discontinued sales of the product in the United States.

At the time, Johnson & Johnson explained the move as part of a broader business strategy. "As part of a worldwide portfolio assessment, we have made the commercial decision to transition to an all cornstarch-based baby powder portfolio," the company said.

The transition to cornstarch-based formulas marks a significant shift for one of the company's most recognizable products, though the legal fallout from decades of talc-based powder sales continues to reverberate.

If the settlement gains the necessary approval from plaintiffs' legal representatives, it could mark the conclusion of one of the most significant product liability sagas in recent corporate history. Until then, the outcome remains uncertain.

What are your thoughts on this proposed settlement? Do you believe it adequately addresses the concerns raised by plaintiffs, or should the cases proceed to trial? Share this article and join the conversation.

Source: BBC Business